Maria Jesús Melià

Maria Jesús Melià

Auto-generated profile, based on publicly available information

Maria Jesús Melià

Research Group on Neuromuscular and Mitochondrial Diseases, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2013 in Brain
Verified
Journal Article
Open access
PDF file
CPCeline Perier
Celine Perier
ABAndreas Bender
Andreas Bender
EGElena García-Arumí
Elena García-Arumí
MMMª Jesus Melià
Mª Jesus Melià
JBJordi Bové
Jordi Bové
MVMiquel Vila
Miquel Vila
Acquired alterations in mitochondrial DNA are believed to play a pathogenic role in Parkinson’s disease. In particular, accumulation of mitochondrial DNA deletions has been observed in substantia nigra pars compacta dopaminergic neurons from patients with Parkinson’s disease and aged individuals. Also, mutations in mitochondrial DNA polymerase gamma result in multiple mitochondrial DNA deletions that can be associated with levodopa-responsive parkinsonism and severe substantia nigra pars compacta dopaminergic neurodegeneration. However, whether mitochondrial DNA deletions play a causative role in the demise of dopaminergic neurons remains unknown. Here we assessed the potential pathogenic effects of mitochondrial DNA deletions on the dopaminergic nigrostriatal system by using mutant mice possessing a proofreading-deficient form of mitochondrial DNA polymerase gamma (POLGD257A), which results in a time-dependent accumulation of mitochondrial DNA deletions in several tissues, including the brain. In these animals, we assessed the occurrence of mitochondrial DNA deletions within individual substantia nigra pars compacta dopaminergic neurons, by laser capture microdissection and quantitative real-time polymerase chain reaction, and determined the potential deleterious effects of such mitochondrial DNA alterations on mitochondrial function and dopaminergic neuronal integrity, by cytochrome c oxidase histochemistry and quantitative morphology. Nigral dopaminergic neurons from POLGD257A mice accumulate mitochondrial DNA deletions to a similar extent (∼40–60%) as patients with Parkinson’s disease and aged individuals. Despite such high levels of mitochondrial DNA deletions, the majority of substantia nigra pars compacta dopaminergic neurons from these animals did not exhibit mitochondrial dysfunction or degeneration. Only a few individual substantia nigra pars compacta neurons appeared as cytochrome c oxidase-negative, which exhibited higher levels of mitochondrial DNA deletions than cytochrome c oxidase-positive cells (60.38 ± 3.92% versus 45.18 ± 2.83%). Survival of dopaminergic neurons in POLGD257A mice was associated with increased mitochondrial DNA copy number, enhanced mitochondrial cristae network, improved mitochondrial respiration, decreased exacerbation of mitochondria-derived reactive oxygen species, greater striatal dopamine levels and resistance to parkinsonian mitochondrial neurotoxins. These results indicate that primary accumulation of mitochondrial DNA deletions within substantia nigra pars compacta dopaminergic neurons, at an extent similar to that observed in patients with Parkinson’s disease, do not kill dopaminergic neurons but trigger neuroprotective compensatory mechanisms at a mitochondrial level that may account for the high pathogenic threshold of mitochondrial DNA deletions in these cells.

29 March 2013 in Brain
Verified
Journal Article
Open access
PDF file
MMMaria J. Melià
Maria J. Melià
AKAkatsuki Kubota
Akatsuki Kubota
Saida OrtolanoSaida Ortolano
Saida Ortolano
JVJuan J Vilchez
Juan J Vilchez
JGJosep Gámez
Josep Gámez
RMRamon Marti
Ramon Marti
In 2001, we reported linkage of an autosomal dominant form of limb-girdle muscular dystrophy, limb-girdle muscular dystrophy 1F, to chromosome 7q32.1-32.2, but the identity of the mutant gene was elusive. Here, using a whole genome sequencing strategy, we identified the causative mutation of limb-girdle muscular dystrophy 1F, a heterozygous single nucleotide deletion (c.2771del) in the termination codon of transportin 3 (TNPO3). This gene is situated within the chromosomal region linked to the disease and encodes a nuclear membrane protein belonging to the importin beta family. TNPO3 transports serine/arginine-rich proteins into the nucleus, and has been identified as a key factor in the HIV-import process into the nucleus. The mutation is predicted to generate a 15-amino acid extension of the C-terminus of the protein, segregates with the clinical phenotype, and is absent in genomic sequence databases and a set of >200 control alleles. In skeletal muscle of affected individuals, expression of the mutant messenger RNA and histological abnormalities of nuclei and TNPO3 indicate altered TNPO3 function. Our results demonstrate that the TNPO3 mutation is the cause of limb-girdle muscular dystrophy 1F, expand our knowledge of the molecular basis of muscular dystrophies and bolster the importance of defects of nuclear envelope proteins as causes of inherited myopathies.

Verified
Journal Article
Open access
PDF file
JRJavier Ramón
Javier Ramón
FVFerran Vila-Julià
Ferran Vila-Julià
DMDavid Molina-Granada
David Molina-Granada
MMMiguel Molina-Berenguer
Miguel Molina-Berenguer
MMMaria Jesús Melià
Maria Jesús Melià
RMRamon Marti
Ramon Marti
Mitochondrial DNA depletion and multiple deletions syndromes (MDDS) constitute a group of mitochondrial diseases defined by dysfunctional mitochondrial DNA (mtDNA) replication and maintenance. As is the case for many other mitochondrial diseases, the options for the treatment of these disorders are rather limited today. Some aggressive treatments such as liver transplantation or allogeneic stem cell transplantation are among the few available options for patients with some forms of MDDS. However, in recent years, significant advances in our knowledge of the biochemical pathomechanisms accounting for dysfunctional mtDNA replication have been achieved, which has opened new prospects for the treatment of these often fatal diseases. Current strategies under investigation to treat MDDS range from small molecule substrate enhancement approaches to more complex treatments, such as lentiviral or adenoassociated vector-mediated gene therapy. Some of these experimental therapies have already reached the clinical phase with very promising results, however, they are hampered by the fact that these are all rare disorders and so the patient recruitment potential for clinical trials is very limited.

3 October 2013 in Genes, Brain and Behavior
Verified
Journal Article
Closed access
PDF file
ABAlbert Blanco-Grau
Albert Blanco-Grau
IBI. Bonaventura‐Ibars
I. Bonaventura‐Ibars
JCJ. Coll‐Cantí
J. Coll‐Cantí
MMM. J. Melià
M. J. Melià
RMR. Martinez
R. Martinez
EGElena García-Arumí
Elena García-Arumí

2 June 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
YCYolanda Camara
Yolanda Camara
LCLidia Carreño-Gago
Lidia Carreño-Gago
Miguel A. MartinMiguel A. Martin
Miguel A. Martin
MMMaria J. Melià
Maria J. Melià
AEAlberto Blazquez Encinar
Alberto Blazquez Encinar
EGElena García-Arumí
Elena García-Arumí

1 November 2002 in Journal of Molecular Biology
Verified
Journal Article
Closed access
GVGuillermo P. Vicent
Guillermo P. Vicent
MMMarı́a J. Meliá
Marı́a J. Meliá
MBMiguel Beato
Miguel Beato